RT Journal Article
SR Electronic
T1 Utility of Cerebrospinal Fluid Protein Levels as a Potential Predictive Biomarker of Disease Severity in HIV-Associated Cryptococcal Meningitis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.10.23299793
DO 10.1101/2023.12.10.23299793
A1 Kasibante, John
A1 Irfanullah, Eesha
A1 Wele, Abduljewad
A1 Okafor, Elizabeth
A1 Ssebambulidde, Kenneth
A1 Okurut, Samuel
A1 Kagimu, Enock
A1 Gakuru, Jane
A1 Rutakingirwa, Morris K.
A1 Mugabi, Timothy
A1 Nuwagira, Edwin
A1 Jjunju, Samuel
A1 Mpoza, Edward
A1 Tugume, Lillian
A1 Nsangi, Laura
A1 Musibire, Abdu K
A1 Muzoora, Conrad
A1 Rhein, Joshua
A1 Meya, David B.
A1 Boulware, David R.
A1 Abassi, Mahsa
YR 2023
UL http://medrxiv.org/content/early/2023/12/12/2023.12.10.23299793.abstract
AB Background Cerebrospinal fluid (CSF) protein levels exhibit high variability in HIV-associated cryptococcal meningitis from being normal to markedly elevated. However, the clinical implications of CSF protein levels in cryptococcal meningitis remain unclear.Methods We analysed data from 890 adults with HIV-associated cryptococcal meningitis randomized into two clinical trials in Uganda between 2015 and 2021. CSF protein was grouped into ≥100 mg/dL (n=249) and <100 mg/dL (n=641). We described baseline clinical variables and mortality by CSF protein levels.Results Approximately one-third of individuals had a baseline CSF protein ≥100 mg/dL. Those with CSF protein ≥100 mg/dL were more likely to present with Glasgow coma scale scores <15 (P<0.01), self-reported seizures at baseline (P=0.02), higher CD4 T-cells (p<0.001), and higher CSF white cells (p<0.001). Moreover, those with a baseline CSF protein ≥100 mg/dL also had a lower baseline CSF fungal burden (p<0.001) and a higher percentage of sterile CSF cultures at day 14 (p=0.02). Individuals with CSF protein ≥100 mg/dL demonstrated a more pronounced immune response consisting of upregulation of immune effector molecules pro-inflammatory cytokines, type-1 T-helper cell cytokines, type-3 chemokines, and immune-exhaustion marker (p<0.05). 18-week mortality risk in individuals with a CSF protein <100 mg/dL was 34% higher, (unadjusted Hazard Ratio 1.34; 95% CI, 1.05 to 1.70; p=0.02) than those with ≥100 mg/dL.Conclusion In cryptococcal meningitis, individuals with CSF protein ≥100 mg/dL more frequently presented with seizures, altered mental status, immune activation, and favourable fungal outcomes. Baseline CSF protein levels may serve as a surrogate marker of immune activation and prognosis.Competing Interest StatementThe authors have declared that no competing interests exist.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approvals for both clinical trials were granted from the Mulago Hospital Research and Ethics Committee, the Uganda National Council of Science & Technology, and the University of Minnesota Institutional Review Board. All participants or their surrogate provided their written consent for study participation.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files.